Hims & Hers Health, Inc. (NYSE:HIMS) Receives $19.86 Consensus Target Price from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received an average recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.86.

HIMS has been the topic of several analyst reports. Jefferies Financial Group boosted their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Finally, Piper Sandler reissued a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $18.75 on Wednesday. The stock has a market cap of $4.03 billion, a P/E ratio of -1,875.00 and a beta of 1.06. Hims & Hers Health has a one year low of $5.65 and a one year high of $25.74. The company has a fifty day moving average price of $16.50 and a 200 day moving average price of $17.31.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) EPS. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.22 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now owns 185,326 shares of the company’s stock, valued at $4,077,172. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the sale, the insider now owns 185,326 shares of the company’s stock, valued at $4,077,172. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,335 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $20.29, for a total transaction of $47,377.15. Following the transaction, the insider now owns 166,809 shares in the company, valued at approximately $3,384,554.61. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 573,618 shares of company stock valued at $9,329,808 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the 2nd quarter valued at about $111,000. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Finally, Amalgamated Bank lifted its position in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.